0.53% -0.045

Grifols Sa Adr (GRFS)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt GRFS? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Grifols Sa Adr Stock (GRFS) Company Profile

Grifols Sa Adr

Healthcare (1117)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GRFS's Discussions on Twitter

Compare GRFS vs LLY, JNJ, ABBV, AZN, NVS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GRFS Grifols Sa Adr	8.42	5.76B	8.51B	568.12M	706.97M	0.6739
LLY Lilly Eli Co	887.40	821.80B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	226.46	555.64B	96.36B	21.04B	19.70B	8.6488
ABBV Abbvie Inc	201.73	360.31B	61.16B	4.19B	17.82B	2.3614
AZN Astrazeneca Plc	197.40	311.24B	58.80B	10.24B	8.98B	3.2788
NVS Novartis Ag Adr	148.51	288.11B	54.72B	14.02B	15.32B	7.1855

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-12	Fortgesetzt	Morgan Stanley	Overweight
2024-03-12	Herabstufung	Deutsche Bank	Hold → Sell
2023-04-12	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-03-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-02-16	Hochstufung	Barclays	Underweight → Equal Weight
2023-01-18	Hochstufung	Jefferies	Hold → Buy
2022-04-08	Eingeleitet	Morgan Stanley	Equal-Weight
2021-11-05	Herabstufung	Deutsche Bank	Buy → Hold
2021-10-19	Herabstufung	Barclays	Overweight → Underweight
2021-10-06	Hochstufung	Citigroup	Neutral → Buy
2021-06-14	Hochstufung	Deutsche Bank	Hold → Buy
2021-04-20	Eingeleitet	Deutsche Bank	Hold
2021-03-23	Hochstufung	Credit Suisse	Neutral → Outperform
2021-03-11	Hochstufung	HSBC Securities	Hold → Buy
2020-10-01	Hochstufung	Citigroup	Sell → Neutral
2020-06-09	Herabstufung	Citigroup	Neutral → Sell
2020-06-09	Hochstufung	HSBC Securities	Reduce → Hold
2020-03-25	Herabstufung	Citigroup	Buy → Neutral
2019-06-27	Hochstufung	JP Morgan	Neutral → Overweight
2019-02-08	Herabstufung	Berenberg	Buy → Hold
2018-10-11	Hochstufung	Berenberg	Hold → Buy
2018-06-01	Eingeleitet	Barclays	Overweight
2017-10-31	Eingeleitet	Citigroup	Buy
2017-06-30	Herabstufung	Goldman	Buy → Neutral
2017-04-06	Eingeleitet	BofA/Merrill	Buy
2017-01-03	Hochstufung	JP Morgan	Neutral → Overweight
2016-02-09	Hochstufung	Berenberg	Hold → Buy
2016-01-04	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2015-12-02	Herabstufung	HSBC Securities	Buy → Hold
2015-11-20	Herabstufung	Berenberg	Buy → Hold
2015-04-28	Herabstufung	Berenberg	Buy → Hold

Alle ansehen

Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten

Finanzdaten der Grifols Sa Adr-Aktie (GRFS)

Grifols Sa Adr (GRFS)

Grifols Sa Adr Stock (GRFS) Company Profile

Compare GRFS vs LLY, JNJ, ABBV, AZN, NVS

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten

Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan

CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView

Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS

Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK

Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewswire Inc.

Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS

Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS

The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent

Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS

Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS

Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha

Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India

Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com

Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada

ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz

Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World

Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS

Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets

Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha

European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛

Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView

Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq

Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK

Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN

Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent

Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq

Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha

GRDLY Stock Price, Quote and News - Markets.com

Grifols Announces Interim Dividend for 2025 - The Globe and Mail

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail

Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha

6 undervalued stocks with low beta - Morningstar

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha

Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance

Spanish court opens investigation into Gotham City's attack on Grifols - Reuters

Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance

China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research

Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research

Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha

Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm

Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire

Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers

The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent

Finanzdaten der Grifols Sa Adr-Aktie (GRFS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie GRFS